Oncology
Viracta Therapeutics Inc. focuses on advanced cancer and relapsed/refractory lymphomas, with particular interest in solid and hematologic malignancies that remain difficult to treat.
- Advanced cancer
- Relapsed/refractory lymphoma
- Epstein-Barr virus-positive malignancy
The company’s research activity centers on cancers with limited treatment options, including disease settings marked by recurrence and resistance to prior therapy.
Virus-associated malignancies
The sponsor has a clear therapeutic interest in Epstein-Barr Virus-positive (EBV+) lymphoma, reflecting work in cancers linked to viral infection and viral-driven tumor biology.
- EBV-positive lymphoma
- Virus-driven cancer
- Viral oncology
This area includes malignancies where viral persistence and tumor behavior are closely connected, shaping a distinct oncology focus.
Therapeutic development in hematologic cancer
Clinical research activity includes treatment strategies for hematologic cancers, especially lymphoma populations with unmet need after prior treatment failure.
- Lymphoma therapy
- Refractory disease
- Oncology treatment response
The sponsor’s trial portfolio is concentrated on assessing antitumor activity in blood cancers rather than broad multi-disease development.
Small-molecule epigenetic and antiviral combination strategies
Viracta Therapeutics Inc. also studies combination treatment approaches designed for virus-associated cancers, including regimens that link epigenetic modulation with antiviral therapy.
- Epigenetic cancer therapy
- Antiviral combination treatment
- Targeted oncology therapy
Its clinical research landscape includes interest in how these approaches may be applied to tumors with viral dependence and persistent disease activity.
